In a report issued on November 19, Scott Henry from Roth Capital reiterated a Hold rating on Tonix Pharma (TNXP), with a price target of $0.75. The company’s shares closed on Wednesday at $0.46, close to its 52-week low of $0.45.
According to TipRanks.com, Henry is a 4-star analyst with an average return of 2.5% and a 42.2% success rate. Henry covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, RedHill Biopharma, and Intec Pharma Ltd.
The the analyst consensus on Tonix Pharma is currently a Hold rating.
See today’s analyst top recommended stocks >>
Based on Tonix Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.48 million. In comparison, last year the company had a GAAP net loss of $5.79 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tonix Pharmaceuticals Holding Corp. operates as a clinical-stage pharmaceutical company, which engages in the development of pharmaceutical products for public health challenges. It focuses on delivering an efficacious, and safe long-term treatment for posttraumatic stress disorder. It offers TNX-102 SL, TNX-601, TNX-801, TNX-301, and TNX-701.
